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of these patients in the community compared to patients
in the severe stage who tend to be institutionalized. Based
on its slowing of Alzheimer’s patient deterioration,
rivastigmine would save annually $268 million (14.2%)
of total productivity costs to employers and $1.41 billion
(14.2%) of total income losses to caregivers. Rivastig-
mine’s effects in slowing Alzheimer’s patient deterioration
are strongest in the moderate disease stage. Coupled with
higher employment-related costs in this stage, rivastig-
mine’s cost-saving effects would also be highest in the
moderate disease stage.
CONCLUSION: Employment-related costs of informal
Alzheimer’s caregiving are substantial. Therapies such as
rivastigmine can signiﬁcantly reduce these costs, particu-
larly in the moderate disease stage where costs and
rivastigmine’s effects are greatest.
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OBJECTIVES: The purpose of this study is to estimate
the impact of anxiety on absenteeism and employment 
in the United States using the 1997 Medical Expenditure
Panel Survey.
METHODS: Anxiety cases were deﬁned by self-report 
by survey respondents who saw a physician during the
previous year for a condition and recorded as a three 
digit ICD-9 code (Anxiety disorders = 300). National
population estimates were derived from patient level
weights as determined by a nationally representative
sample of the non-institutionalized civilian population of
the United States in 1997. Descriptive analyses were used
to examine individual demographic, socioeconomic, and
co-morbidity characteristics of those respondents with
anxiety.
RESULTS: Of the 1997 US representative population of
34,551 survey respondents from the MEPS analysis, 848
persons, representing 684,312 persons (2.5% of the US
population), reported having anxiety. Anxiety respon-
dents were more likely to be female (69.2%), Caucasian
(83.6%), and older than the overall population (mean age
44 years vs. 33 years). Among respondents aged 18–64
years, persons with anxiety were less likely to work than
those without anxiety (males 59.1% vs. 70.8%; females
53.5% vs. 56.9%). Those persons reporting anxiety were
more likely to have missed days from work 39.1% vs.
28.2% for females and 35.9% vs. 27.5% for males.
Persons with anxiety were more likely to change jobs
through the year and a half interview reference period
(57.8% vs.49.2% for females; 63.9% vs. 57.4% for
males).
CONCLUSIONS: Differences are seen at the workplace
in patients with and without anxiety disorders. Patients
with anxiety most often are female and have a greater fre-
quency of not being employed, missing time from work,
and changing jobs.
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OBJECTIVE: An estimated 50% of Americans are
exposed to at least one traumatic event in a lifetime. Of
those, 20% experience post-traumatic stress disorder
(PTSD). Approximately 50% of patients with PTSD have
comorbid major depression disorder. This study exam-
ined the cost differential between patients with major
depressive disorder (MDD) only, PTSD only and patients
with comorbid MDD and PTSD.
METHODS: A retrospective study of patients with MDD
and PTSD was performed using 1996 to 1999 claims
from the MarketScan Database, with private sector health
data from approximately 100 payers. Three cohorts of
patients were created: 1) patients with MDD (ICD-9-CM
296.2, 296.3, 300.4, or 311); 2) patients with PTSD
(ICD-9-CM 309.81); and 3) patients with both MDD and
PTSD. Patients had to also have a prescription drug claim
for an antidepressant within 30 days of diagnosis. During
the 6 month follow-up, healthcare utilization and expen-
ditures for inpatient, outpatient, emergency room, and
outpatient drugs were calculated. Total expenditures were
compared. ANOVA was used to assess the statistical 
signiﬁcance of differences in expenditures.
RESULTS: A total of 24,955 patients with fee-for-service
health coverage were identiﬁed. Of those, 24,156 were
diagnosed with MDD, 196 with PTSD, and 603 had 
co-occurring MDD and PTSD. The mean total expendi-
ture for patients with MDD, PTSD, and MDD with PTSD
were $3,407, $3,714, $5,723 respectively (p < 0.05).
PTSD was signiﬁcantly associated with increased expen-
ditures after stratifying for gender, age, and geographic
region.
CONCLUSION: Costs associated with MDD and PTSD
are substantial. The total health care expenditures of
patients with PTSD were signiﬁcantly higher than 
expenditures for patients with MDD alone. Patients 
with comorbid depression and PTSD had signiﬁcantly
increased expenditures than patients with one condition.
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